BMS expands biologics facility in MA

By Melissa Fassbender

- Last updated on GMT

Bristol-Myers Squibb has completed an expansion at its Devens, MA, biologics facility. (Photo: Business Wire)
Bristol-Myers Squibb has completed an expansion at its Devens, MA, biologics facility. (Photo: Business Wire)
Bristol-Myers Squibb (BMS) has completed an expansion of its Devens, MA-based biologics facility to support the company’s growing biologics medicines portfolio.

The $280m project increases the site’s workforce by around 200 and adds two new buildings to the 89-acre campus. The expansion project brings the company’s total investment in the site to more than $1bn.

The new facilities add approximately 200,000 square feet in space, and will include a Biologics Development Building for designing processes for investigational medicines’ early production, and a Clinical Manufacturing Building where the medicines will be produced to support clinical trials.

This project represents a significant expansion in the site’s size and mission​,” said Greg Guyer, senior vice president, Biologics Development and Operations.

According to the company, both are new capabilities for the campus, which previously focused on large-scale, bulk biologics manufacturing.

Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies​,” said Lou Schmukler, president, Global Manufacturing & Supply. “Bringing together biologics development and clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide​.” 

Related topics Bio developments Facilities

Related news

Show more

Related suppliers

Follow us

Webinars

Follow us